会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS
    • 氯化唑和噻唑化合物作为KSP抑制剂
    • WO2011128388A3
    • 2013-03-14
    • PCT/EP2011055855
    • 2011-04-13
    • NOVARTIS AGBARSANTI PAUL ADING YUHAN WOOSEOK
    • BARSANTI PAUL ADING YUHAN WOOSEOK
    • C07D263/32A61K31/421A61K31/422A61K31/426A61K31/427A61P35/00C07D277/28C07D413/12C07D417/12C07D417/14
    • A61K31/427A61K31/422A61K31/426A61K31/437A61K45/06C07D263/32C07D277/28C07D413/12C07D417/12C07D417/14C07D471/04
    • Disclosed are substituted oxazole and thiazole compounds of Formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 is selecled from the group consisting of alkyl, branched alkyl, and substituted alkyl; R2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R3 is selected from the group consisting of -L1-A1 wherein L1 is selected from the group consisting of -C(O)-, -C(S)-, -S(O)- and -S(O)2- and A1 is selected from the group consisting, of alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted- cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl;, and NR8R9; R4 is selected from the group consisting of hydrogen, alkyl substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl, and optionally substituted pyrrolidinyl; or R3 and R4 together with the nitrogen atom bound thereto join to form a five to seven member heterocycloalkyl or substituted heterocycloalkyl group where optionally one carbon ring atom is selected from the group consisting of O, S, or NR11; X is Q or S; R6 is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, all of which may be optionally substituted with -(R10)m where R10 is as defined herein, m is 1, 2, 3, or 4, and each R10 may be the same or different when m is 2, 3, or 4; R7 is -L2-A2 wherein L2 is C1-C5 aJkylene and A2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, The compounds of Formula (I) are useful for treating KSP mediated diseases, including cancer.
    • 公开了式(I)的取代的恶唑和噻唑化合物或其药学上可接受的盐:其中:R1由烷基,支链烷基和取代的烷基取代; R2选自氢,烷基和取代的烷基; R3选自-L1-A1,其中L1选自-C(O) - , - C(S) - , - S(O) - 和-S(O)2 - ,和 A 1选自烷基,取代的烷基,烷氧基,取代的烷氧基,芳基,取代的芳基,杂芳基,取代的杂芳基,环烷基,取代的 - 环烷基,杂环烷基,取代的杂环烷基和NR8R9。 R4选自氢,烷基取代的烷基,烯基,取代的烯基,炔基和取代的炔基,以及任选取代的吡咯烷基; 或者R 3和R 4与其结合的氮原子一起形成五至七元杂环烷基或取代的杂环烷基,其中任选一个碳环原子选自O,S或NR 11; X为Q或S; R 6选自环烷基,杂环烷基,芳基和杂芳基,其全部可以任选被 - (R 10)m取代,其中R 10如本文所定义,m为1,2,3或4,且各自为 当m为2,3或4时,R10可以相同或不同; R7是-L2-A2,其中L2是C1-C5亚氨基,A2选自芳基,取代的芳基,杂芳基,取代的杂芳基,环烷基,取代的环烷基,杂环烷基和取代的杂环烷基。式(I) 可用于治疗KSP介导的疾病,包括癌症。